ArticleMolecular biology reports2026
Integrated bulk, single-cell and spatial transcriptomic analyses identify KIFC1 as a driver of malignant progression in lung adenocarcinoma.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundKinesin family member C1 (KIFC1), a minus-end-directed kinesin motor protein, has been implicated in centrosome clustering and tumor progression. However, its cellular distribution and potential roles in malignant cell plasticity and tumor microenvironment-associated signaling in lung adenocarcinoma (LUAD) remain incompletely understood.
methodsTCGA-LUAD, single-cell RNA sequencing (E-MTAB-6149), and spatial transcriptomic data (GSE307534) were analyzed to characterize KIFC1 expression patterns and clinical significance. Functional enrichment, cell-cell communication, virtual-knockout, and cell-state trajectory analyses were performed to investigate KIFC1-associated biological programs. Drug sensitivity was computationally estimated, with particular attention to erlotinib, and exploratory molecular docking was performed. The effects of KIFC1 knockdown on LUAD cell proliferation, migration, invasion, tumorsphere formation, and epithelial-mesenchymal transition (EMT) were evaluated in vitro.
resultsKIFC1 was significantly overexpressed in LUAD and was associated with unfavorable overall survival. Single-cell and spatial transcriptomic analyses showed that KIFC1 was predominantly expressed in malignant epithelial cells and increased across advanced malignant cell states and pathological stages. KIFC1-high malignant cells exhibited enhanced cell-cycle activity, stemness, and EMT programs. Computational analyses further associated these cells with MIF- and SPP1-related intercellular signaling. KIFC1 knockdown significantly inhibited proliferation, colony formation, tumorsphere formation, migration, invasion, and EMT. Drug-response prediction indicated a higher estimated erlotinib IC50 in KIFC1-high tumors, suggesting potentially reduced responsiveness that requires experimental validation.
conclusionKIFC1 is associated with malignant progression, stemness, and EMT in LUAD. Computational analyses additionally suggest a potential relationship between KIFC1-associated malignant states and tumor microenvironmental signaling, supporting its value as a prognostic biomarker and potential therapeutic target.
Indexed as
Identifiers
42611083What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.